| Autor: |
Han, Wanting, Liu, Mingyu, Han, Dong, Li, Muqing, Toure, Anthia A., Wang, Zifeng, Besschetnova, Anna, Patalano, Susan, Macoska, Jill A., Gao, Shuai, He, Housheng Hansen, Cai, Changmeng |
| Zdroj: |
Oncogene; 20220101, Issue: Preprints p1-13, 13p |
| Abstrakt: |
Genomic loss of RB1is a common alteration in castration-resistant prostate cancer (CRPC) and is associated with poor patient outcomes. RB1loss is also a critical event that promotes the neuroendocrine transdifferentiation of prostate cancer (PCa) induced by the androgen receptor (AR) signaling inhibition (ARSi). The loss of Rb protein disrupts the Rb-E2F repressor complex and thus hyperactivates E2F transcription activators. While the impact of Rb inactivation on PCa progression and linage plasticity has been previously studied, there is a pressing need to fully understand underlying mechanisms and identify vulnerabilities that can be therapeutically targeted in Rb-deficient CRPC. Using an integrated cistromic and transcriptomic analysis, we have characterized Rb activities in multiple CRPC models by identifying Rb-directly regulated genes and revealed that Rb has distinct binding sites and targets in CRPC with different genomic backgrounds. Significantly, we show that E2F1 chromatin binding and transcription activity in Rb-deficient CRPC are highly dependent on LSD1/KDM1A, and that Rb inactivation sensitizes CRPC tumor to the LSD1 inhibitor treatment. These results provide new molecular insights into Rb activity in PCa progression and suggest that targeting LSD1 activity with small molecule inhibitors may be a potential treatment strategy to treat Rb-deficient CRPC. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink